SUNDARARAJAN, Pavithra,SHETH, Agam,KUIPER, Jesse,MARSAC, Patrick Jules,MILLER, Elise,MOSER, Justin David,SOCIA, Adam,WAGNER, Angela, M.
申请号：
EP15746556
公开号：
EP3102211A4
申请日:
2015.02.03
申请国别(地区):
EP
年份:
2017
代理人:
摘要：
The present disclosure is directed to compositions comprising blended materials comprising a first solid dispersion formulation, which comprises an HCV NS3/NS4a protease inhibitor or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable polymers or a mixture thereof, and optionally one or more pharmaceutically acceptable surfactants or a mixture thereof a second solid dispersion formulation, which comprises an HCV NS5a inhibitor or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable polymers or a mixture thereof and optionally one or more pharmaceutically acceptable surfactants or a mixture thereof and optionally one or more excipients. The present disclosure is also directed to oral dosage forms, such as tablets or capsules comprising the disclosed blended compositions comprising the disclosed solid dispersion formulations, and the methods for making these solid dispersion formulations and pharmaceutical compositions.
